ERAS
Price
$1.74
Change
+$0.03 (+1.75%)
Updated
Jul 25 closing price
Capitalization
492.92M
12 days until earnings call
TSHA
Price
$2.65
Change
+$0.06 (+2.32%)
Updated
Jul 25 closing price
Capitalization
693.06M
23 days until earnings call
Interact to see
Advertisement

ERAS vs TSHA

Header iconERAS vs TSHA Comparison
Open Charts ERAS vs TSHABanner chart's image
Erasca
Price$1.74
Change+$0.03 (+1.75%)
Volume$654.4K
Capitalization492.92M
Taysha Gene Therapies
Price$2.65
Change+$0.06 (+2.32%)
Volume$2.83M
Capitalization693.06M
ERAS vs TSHA Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. TSHA commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and TSHA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (ERAS: $1.74 vs. TSHA: $2.65)
Brand notoriety: ERAS and TSHA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 56% vs. TSHA: 74%
Market capitalization -- ERAS: $492.92M vs. TSHA: $693.06M
ERAS [@Biotechnology] is valued at $492.92M. TSHA’s [@Biotechnology] market capitalization is $693.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileTSHA’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • TSHA’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than TSHA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while TSHA’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 5 bearish.
  • TSHA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than TSHA.

Price Growth

ERAS (@Biotechnology) experienced а +16.00% price change this week, while TSHA (@Biotechnology) price change was +3.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

TSHA is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TSHA($693M) has a higher market cap than ERAS($493M). TSHA YTD gains are higher at: 53.179 vs. ERAS (-30.677). TSHA has higher annual earnings (EBITDA): -85.47M vs. ERAS (-150.24M). ERAS has more cash in the bank: 305M vs. TSHA (117M). ERAS has less debt than TSHA: ERAS (50.8M) vs TSHA (61.4M). TSHA has higher revenues than ERAS: TSHA (7.22M) vs ERAS (0).
ERASTSHAERAS / TSHA
Capitalization493M693M71%
EBITDA-150.24M-85.47M176%
Gain YTD-30.67753.179-58%
P/E RatioN/A2.70-
Revenue07.22M-
Total Cash305M117M261%
Total Debt50.8M61.4M83%
TECHNICAL ANALYSIS
Technical Analysis
ERASTSHA
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 16 days ago
88%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CMVIX26.88N/A
N/A
BlackRock Advantage Large Cap Gr Instl
KGDIX32.60N/A
N/A
DWS Global Small Cap Inst
JCMAX65.03N/A
N/A
JPMorgan Mid Cap Equity A
MNECX20.33N/A
N/A
Manning & Napier Pro-Blend Extnd Term L
MSDQX14.17N/A
N/A
Morgan Stanley Emerging Mkt ex China A

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.75%
XNCR - ERAS
54%
Loosely correlated
N/A
RVMD - ERAS
53%
Loosely correlated
+1.84%
LRMR - ERAS
52%
Loosely correlated
+3.47%
OCUL - ERAS
51%
Loosely correlated
+2.43%
BEAM - ERAS
51%
Loosely correlated
+3.68%
More